PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist. It primarily acts through melanocortin receptors, particularly MC3R and MC4R, within the central nervous system and has been investigated for its role in neural pathways associated with sexual behavior, sexual desire, and related physiological processes.
Unlike conventional approaches that primarily rely on peripheral vascular mechanisms, research on Bremelanotide has focused on central melanocortin signaling and its modulation of neural pathways involved in sexual desire and arousal. PT-141 has also been investigated in melanocortin receptor pharmacology, neurobiology, and related signaling research.
Bremelanotide has been approved by the U.S. FDA for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in a specific patient population. As a research material, PT-141 may be used in receptor pharmacology, melanocortin signaling, and neuroendocrine research.